e-therapeutics (AIM: ETX) is an Oxford, UK-based company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology. It uses its highly productive Network-Driven Drug Discovery ("NDD") platform to develop internally-owned, IP-protected, pre-clinical drug discovery assets and is currently developing two programmes in immuno-oncology. The approach has been validated in multiple areas of biology and the company is currently pursuing NDD platform deals with biopharmaceutical companies in numerous, commercially-attractive disease areas. The NDD platform is a combination of large-scale, proprietary databases and a suite of powerful computational tools that employ network analysis, data mining, machine learning, AI and optimisation. The company believes that its revolutionary computer-based platform more realistically reflects the true complexity of disease, with its multiple and often interconnected cellular pathways. The company’s in-silico techniques provide benefits in terms of cost and time savings and lead to a deeper understanding of biology with the ultimate goal of the identification of new and better drugs.
Directors and committees
Details of e-therapeutics’ Board of Directors, including biographical information is available here.
A description of the responsibilities of the Directors and details of Board committees and their responsibilities is available here.
Country of incorporation and main country of operation
e-therapeutics plc is incorporated in England and Wales. Its main country of operation is the UK.
Current constitutional documents
The Company’s articles of association are available here.
Securities in issue
Details of the number of AIM securities in issue, the percentage of AIM securities that is not in public hands and the identity and percentage holdings of its significant shareholders are available here.
Annual accounts and interim reports
Copies of the Company’s annual reports and interim financial statements may be accessed here.
Notifications, admission document and circulars
Click on the links below for access to the following documents:
- all regulatory announcements issued in the last five years
- circulars, notifications or similar publications sent to shareholders by the Company in the last five years
- the most recent admission document
Details of the Company’s corporate governance arrangements are available here.
The Company is subject to the UK City Code on Takeovers and Mergers.
Details of the Company’s nominated advisor and other key advisors may be found here.